The role of steroids in treating diabetic macular oedema in the era of anti-VEGF

Eye (Basingstoke)

Volumn 34, Issue 6, 2020, Pages 1003-1005

  Weinberg, Tamir ^a,b   Loewenstein, Anat ^c,d  

^a HEBREW UNIVERSITY   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB;

ARTERIAL THROMBOEMBOLISM; COMBINATION DRUG THERAPY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; EDITORIAL; EXUDATE; HUMAN; META ANALYSIS (TOPIC); PREGNANT WOMAN; PSEUDOPHAKIA; RETINA FOVEA; STEROID THERAPY; SYSTEMATIC REVIEW (TOPIC); TREATMENT REFUSAL; TREATMENT RESPONSE; VITRECTOMY; DIABETES MELLITUS; DIABETIC RETINOPATHY; MACULAR EDEMA;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; STEROIDS;

EID: 85076880047     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/s41433-019-0739-x     Document Type: Editorial

References (25)

1. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64. DOI: 10.2337/dc11-1909
2. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–58. DOI: 10.1016/j.preteyeres.2011.05.002
3. Global trends in retina ASRS 2018. In: Singh RP, Stone TW. editors. Chicago: IL, 2018. https://www.asrs.org/content/documents/2018-global-trends-in-retina-survey-highlights-website.pdf.
4. Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved DMO with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136:257–69. DOI: 10.1001/jamaophthalmol.2017.6565
5. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134:278–85. DOI: 10.1001/jamaophthalmol.2015.5346
6. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351–9. DOI: 10.1016/j.ophtha.2016.02.022
7. Willis JR, Morse LS, Rich W, Lum F, Salman C, Cantrell A. Treatment patterns for diabetic macular edema (DME) in the United States: analysis of the IRIS® registry (Intelligent Research in Sight). Honolulu, Hawaii: Paper presented at ARVO 2018; 2018.
8. Polizzi S, Mahajan VB. Intravitreal anti-VEGF injections in pregnancy: case series and review of literature. J Ocul Pharm Ther. 2015;31:605–10. DOI: 10.1089/jop.2015.0056
9. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88:e136. DOI: 10.1111/j.1755-3768.2009.01572.x
10. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. DOI: 10.1016/j.ophtha.2011.12.039
11. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247–54. DOI: 10.1016/j.ophtha.2014.05.006
12. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. RISE and RIDE. Ophthalmology. 2013;120:2013–22. DOI: 10.1016/j.ophtha.2013.02.034
13. Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014;132:1317–26. DOI: 10.1001/jamaophthalmol.2014.2333
14. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134:21–9. DOI: 10.1001/jamaophthalmol.2015.4070
15. Sigurdsson R, Begg IS. Organised macular plaques in exudative diabetic maculopathy. Br J Ophthalmol. 1980;64:392–7. DOI: 10.1136/bjo.64.6.392
16. Mehta H, Fraser-Bell S, Yeung A, Campain A, Lim LL, Quin GJ, et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. Br J Ophthalmol. 2016;100:1000–4. DOI: 10.1136/bjophthalmol-2015-307797
17. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–9. DOI: 10.1016/j.ophtha.2008.06.015
18. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. DOI: 10.1016/j.ophtha.2014.04.024
19. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14. DOI: 10.1016/j.ophtha.2010.12.033
20. Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136:29–38. DOI: 10.1001/jamaophthalmol.2017.4914
21. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556–60. DOI: 10.1097/00006982-200507000-00002
22. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915–23. DOI: 10.1097/IAE.0b013e318206d18c
23. Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155–70. DOI: 10.1016/j.ophtha.2019.03.023
24. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161–6420(18)33018-5. 10.1016/j.ophtha.2019.04.017. (In press) DOI: 10.1016/j.ophtha.2019.04.017
25. Callanan D, Kunimoto D, Maturi RK, Patel SS, Staurenghi G, Wolf S, et al. Double-masked, randomized, phase 2 evaluation of abicipar pegol (an anti-VEGF DARPin therapeutic) in neovascularage-related macular degeneration. J Ocul Pharmacol Ther. 2018. 10.1089/jop.2018.0062. (In press) DOI: 10.1089/jop.2018.0062